Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.
- 20 May 2019
- journal article
- conference paper
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl), 9547
- https://doi.org/10.1200/jco.2019.37.15_suppl.9547